Sionna Therapeutics (SION) Preferred Stock Liabilities (2024)
Sionna Therapeutics' (SION) quarterly Preferred Stock Liabilities came in at $330.4 million in Q4 2024, up 82.19% quarter-over-quarter from $181.3 million in Q3 2024.
Sionna Therapeutics (SION) Preferred Stock Liabilities (2024) Analysis & Trends
Sionna Therapeutics has disclosed Preferred Stock Liabilities across 1 years of filings, most recently posting $330.4 million for Q4 2024.
- Preferred Stock Liabilities for Q4 2024 came in at $330.4 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2024 was $330.4 million (changed N/A YoY), and the FY2024 annual result was $330.4 million, changed N/A from the prior year.
- Preferred Stock Liabilities came in at $330.4 million for Q4 2024 at Sionna Therapeutics, up from $181.3 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $330.4 million in Q4 2024 to a low of $13.0 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | - |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Sionna Therapeutics | 1.61 Bn | 1.61 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 330.37 Mn |
| Sep 30, 2024 | 181.33 Mn |
| Jun 30, 2024 | 13.01 Mn |
| Mar 31, 2024 | 110.79 Mn |